cbd anxiety study

Cbd anxiety study

Animal studies, and self-reports or research in humans, suggest CBD may also help with:

A significant safety concern with CBD is that it is primarily marketed and sold as a supplement, not a medication. Currently, the FDA does not regulate the safety and purity of dietary supplements. So, you cannot be sure that the product you buy has active ingredients at the dose listed on the label. In addition, the product may contain other unknown elements. We also don’t know the most effective therapeutic dose of CBD for any particular medical condition.

The evidence for cannabidiol health benefits

The Farm Bill removed all hemp-derived products, including CBD, from the Controlled Substances Act, which criminalizes the possession of drugs. In essence, this means that CBD is legal if it comes from hemp, but not if it comes from cannabis (marijuana) – even though it is the exact same molecule. Currently, many people obtain CBD online without a medical marijuana license, which is legal in most states.

Cannabidiol (CBD) is often covered in the media, and you may see it touted as an add-in booster to your post-workout smoothie or morning coffee. You can even buy a CBD-infused sports bra. But what exactly is CBD? And why is it so popular?

Is CBD safe?

CBD has been touted for a wide variety of health issues, but the strongest scientific evidence is for its effectiveness in treating some of the cruelest childhood epilepsy syndromes, such as Dravet syndrome and Lennox-Gastaut syndrome (LGS), which typically don’t respond to antiseizure medications. In numerous studies, CBD was able to reduce the number of seizures, and, in some cases, stop them altogether. Epidiolex, which contains CBD, is the first cannabis-derived medicine approved by the FDA for these conditions.

Cbd anxiety study

A total of 430 people started the survey, of whom 15 (3.48%) did not respond to any questions, and 28 (6.5%) reported they did not use CBD themselves (analysis of these non-users can be found in the supplementary materials). Non-CBD-users skipped most questions and had sociodemographic characteristics similar to those of CBD users. Three hundred eighty-seven (90%) reported using CBD themselves. The majority of users were females from the UK (see Table 1). In regards to other medication use, there were a total of 467 responses. 39.4% of respondents reported not taking any other medication, 14.7% “painkillers”, and 14.7% “other” (40% anxiolytics and antidepressants). No other medication was reported by more than 10% of responses.

A cross-sectional study of 2409 cannabidiol users from the USA found that the top three medical conditions reported were chronic pain, arthritis/joint pain, and anxiety, followed by depression and insomnia (Corroon and Phillips 2018). A recent survey carried out by Wheeler et al. of 340 young adults, some of whom were CBD users, found the top reasons to be stress relief, relaxation, and sleep improvement. They found edible CBD products to be the most prevalent (Wheeler et al. 2020). Another study of 400 CBD patients in New Zealand observed an increase in overall quality of life, a decrease in perceived pain, depression, and anxiety symptoms, as well as an increase in appetite and better sleep (Gulbransen et al. 2020).

CBD use patterns

Logistic regression on location purchased (CBD shop or other) found that those who lived outside of the UK (aOR 2.286, [95% CI 1.35–3.86], p = 0.002) and males (aOR 1.75, [95% CI 1.06–2.88], p = 0.02) had greater odds of purchasing CBD from an “other” location. Each of the primary disorders was included in the model individually, and did not significantly alter the model and were not associated with location purchased.

Those aged 35–54 years old (33.9%; aOR 0.60, [95% CI 0.363–0.995], p = 0.048) and 55+ (31.9%; aOR 0.526, [95% CI 0.287–0.964], p = 0.038) had lower odds of using CBD for general health and wellbeing than those aged 18–34 years old (47.7%). Moreover, those aged 35–54 years old (37.1%, aOR 0.561, [95% CI 0.346–0.911], p = 0.019) and 55+ (20.9%; aOR 0.249, [95% CI 0.132–0.470], p ≤ 0.001) had lower odds of using CBD for stress versus those aged 18–34 years old (51.4%). Those aged 34–55 (24.8%) had greater odds of using CBD for chronic pain versus 18–34 years old (14.7%; aOR 2.093, [95% CI 1.122–3.905], p = 0.02). Those aged 55+ (5.1%) had lower odds of using CBD for post-workout sore muscles than 18–34 years old (15.5%; aOR 0.302, [95% CI 0.105–0.868], p = 0.026). Those aged 35–54 years old (43.5%; aOR 0.464, 95% CI 0.28–0.76, p = 0.002) and 55+ (19.8%; aOR 0.149, [95% CI = 0.077, 0.289], p < 0.001) had lower odds of using CBD for self-perceived anxiety versus 18–34 years old (60.4%). Use of CBD for arthritic/joint pain was higher in those 55+ (41.8%) (aOR 8.569, 95% CI [3.792–19.363], p < 0.001) and 35–54 years old (16.7%; aOR 2.295, [95% CI 1.041, 5.061], p = 0.04) in comparison to those 18–34 years old. Those aged 34–55 years old (5.9%) had lower odds of using CBD for skin conditions than those aged 18–34 years old (14.7% aOR 0.42, [95% CI 0.10–0.93], p = 0.03) and those aged 55+ (4.4%) had lower odds of using CBD to improve focus than those aged 18–34 years old (15.3%; aOR 0.248, [95% CI 0.08–0.77], p = 0.017). Moreover, those aged 55+ (23.1% versus 18–34 years old: 41.4%) had lower odds of using CBD for sleep improvement (aOR 0.4, [95% CI 0.21, 0.75], p = 0.004). For endometriosis and menstrual problems, we removed sex from the model finding those aged 34–55 had lower odds of using CBD for menstrual problems (aOR 0.379, [95% CI 0.18–0.796], p = 0.01). Endometriosis did not vary by age. Depression, PTSD, fibromyalgia, ADHD, headache, asthma, THC counteract effects, and restless legs did not vary by sex or age. Confidence intervals could not be generated for Parkinson’s disease, Alzheimer’s disease, autism, multiple sclerosis, epilepsy, cancer, and nausea due to small sample sizes.


Younger respondents were more likely to use novel routes of administration, e.g., vaping or drinking. This trend correlates with data showing that more people have tried vaping (in general) amongst younger age groups (Vaping and e-cigarette use by age U.S 2018). Only 9.3% reported vaping CBD in our sample, compared with 19% in the study by Corroon et al. (Corroon and Phillips 2018). The fast onset of vaporised CBD might explain why inhaled CBD is popular for self-perceived anxiety and stress.